Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- HER2 Positive Breast Cancer
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Triple (Participant, Care Provider, Investigator)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 65 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04170595
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Ze Fei Jiang, Ph.D Affiliated Hospital of Academy of Military Medical Sciences